Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON) | Zendy

Heng Chi | Zendy; Bettina E. Hansen | Zendy; Simin Guo | Zendy; Ning Ping Zhang | Zendy; Xun Qi | Zendy; Liang Chen | Zendy; Qing Guo | Zendy; P. Arends | Zendy; Jiyao Wang | Zendy; Elke Verhey | Zendy; Robert J. de Knegt | Zendy; Qing Xie | Zendy; Harry L.A. Janssen | Zendy

Open Access

Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON)

Author(s) -

Heng Chi,

Bettina E. Hansen,

Simin Guo,

Ning Ping Zhang,

Xun Qi,

Liang Chen,

Qing Guo,

P. Arends,

Jiyao Wang,

Elke Verhey,

Robert J. de Knegt,

Qing Xie,

Harry L.A. Janssen

Publication year - 2017

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1093/infdis/jix024

Subject(s) - medicine , hbeag , gastroenterology , seroconversion , peginterferon alfa 2a , entecavir , combination therapy , pegylated interferon , hepatitis b virus , randomized controlled trial , adverse effect , hepatitis b , immunology , lamivudine , hbsag , chronic hepatitis , virus , ribavirin

We studied whether 48 weeks of pegylated interferon alfa-2b (peginterferon) add-on therapy increases serological response in hepatitis B virus (HBV) envelope antigen (HBeAg)-positive patients receiving nucleos(t)ide analogue (NA) therapy, compared with continued NA monotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research